Mike Needle

Dr. Needle brings more than 20 years of industry experience in clinical, business development, regulatory, and safety. Prior to joining Cybrexa, he served as CMO for Aveo Oncology, Array BioPharma, Multiple Myeloma Research Foundation and Consortium, and was also Vice President, Pediatric Strategy at Celgene. He has three regulatory approvals to his credit including Erbitux for the treatment of colon cancer in the US and Fotivda for the treatment of renal cell carcinoma in the US and the EU. He holds a Doctor of Medicine from State University of New York, Downstate Medical Center, and a Bachelor of Arts in physics at Binghamton University. Dr. Needle is a board-certified pediatric hematologist/oncologist who completed his pediatric oncology training at the Fred Hutchison Cancer Center/University of Washington in Seattle and the MD Anderson Cancer Center in Houston, TX.